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Abstract 
 
Epilepsy is the most common chronic neurological disorder in dogs. Some diets have been 
shown to have a positive impact upon the seizure activity in dogs with idiopathic epilepsy (IE), 
while other diets and dietary supplements (DS), although marketed as providing health 
benefits, lack conclusive scientific evidence on their actual beneficial effects.  
A web-based owner questionnaire was designed to assess how and why owners of dogs with 
IE use different dietary regimes and DS. The study cohort, with 297 valid responses, consisted 
mainly of pure-breed (82.5%) male neutered (52.9%) dogs. Over two-thirds of owners (67.7%) 
changed their dog’s diet after their dog received a diagnosis of IE. Nearly half of the owners 
(45.8%) reported giving DS, the most common being coconut oil or derived medium-chain 
triglyceride oil (71.3%). Some owner justifications of DS use included improvement of seizure 
frequency (88.2%), seizure severity (61.8%) and protection from potential drug side effects 
(62.5%). 
Many owners give DS to their dog with IE. The pharmacokinetic properties of anti-epileptic 
drugs, such as efficacy, absorption and clearance can be influenced by other medications, diets 
and possibly by DS. We propose that use of DS should be considered and monitored by 
veterinary surgeons in epilepsy management. 
 
 
Highlights 
 
 Over 2 3⁄  of owners changed their dog’s diet after the diagnosis of IE. 
 Nearly 1 2⁄  of owners report giving DS on a daily basis supporting epilepsy management. 
 The most common DS types belonged to fatty acid group (94 %). 
 The top three used DS were coconut-, fish- or derived oils, and milk thistle. 
 Reduction of seizure frequency, drug side effects and severity were mainly aimed in DS 
use. 
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List of abbreviations 
 
ABBREVIATIONS 
DS Dietary supplement/s 
AED Anti-epileptic drug 
ADHD attention-deficit/hyperactivity disorder 
CS Cluster Seizure 
LCT Long chain triacylglyceride 
MCT Medium chain triacylglyceride 
Ω-3 FAs omega-3 fatty acids  
QoL Quality of Life 
SE Status Epilepticus 
VFI Voluntary food intake 
 
 
Introduction 
 
Epilepsy is defined as the enduring predisposition of having epileptic seizures (Berendt et al., 
2015), and is the most common chronic neurological disorder in dogs, affecting an estimated 
0.6% of dogs in the general population (Kearsley-Fleet et al., 2013). The chronic, often lifelong 
administration of seizure-suppressing drugs, such as phenobarbital, potassium bromide and 
imepitoin, currently represents the most important form of treatment in veterinary medicine 
(De Risio et al., 2015; Royaux et al., 2017). However, anti-epileptic drug (AED) usage can be 
accompanied by undesirable side effects including polyphagia, sedation, restlessness or ataxia 
which might outweigh the seizure supressing benefits of these medications (Charalambous et 
al., 2014; Charalambous et al., 2016) and negatively affect quality of life (QoL) (Wessmann et 
al., 2016). When conventional AEDs fail to achieve satisfactory seizure control, finding an 
appropriate and effective epilepsy management for the individual can be a difficult and lengthy 
process (Munana, 2013; Podell, 1998; Podell and Fenner, 1993). New treatment strategies are 
needed in epilepsy management (Martle et al., 2014; Munana, 2013; Munana et al., 2012). 
 
Diet is increasingly recognized as having an impact upon the seizure activity and behavior of 
dogs with epilepsy (Bosch et al., 2007; Law et al., 2015; Packer et al., 2016). Ketogenic diets 
(KD) have been shown to be efficient in reducing seizure frequency and severity in human 
patients and rodent models of epilepsy (Achanta and Rae, 2017; Augustin et al., 2018; Lusardi 
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et al., 2015; Mantis et al., 2014; Martle et al., 2014; Patterson, 2014; Wijnen et al., 2017). The 
mechanism of antiepileptic action is not yet fully understood, but might be led by a rise in brain 
ketones improving brain function. KD may have anti-inflammatory properties (Dupuis et al., 
2015) and prevent neuronal hyperexcitability via pH, direct inhibition of ion channels, 
influencing mitochondrial functions and alteration in amino acid metabolism linked to 
inhibitory neurotransmitter production [27, 28].  
 
In addition to complete dietary interventions such as the KD, dietary supplements (DS) of 
different vitamins (Snoeijen-Schouwenaars et al., 2015), minerals (Kumar et al., 2015; Yuen 
and Sander, 2012), fatty acids (Bromfield et al., 2008; Chang et al., 2013; DeGiorgio et al., 
2015; DeGiorgio and Taha, 2016; Taha et al., 2010; Yuen et al., 2012; Yuen et al., 2005) or 
other nutrients (Ciarlone et al., 2016) have been extensively explored in rodent models of 
epilepsy (Betti et al., 2011; Flores-Mancilla et al., 2014; Girotto et al., 2013; Liu et al., 2012; 
Smeland et al., 2012) and human patients (Jackson et al., 2015; Lee and Chung, 2010; Neal et 
al., 2012; Zupec-Kania and Zupanc, 2008). While some studies found that dietary 
supplementation with individual nutrients can improve seizure control (DeGiorgio and Taha, 
2016; Kumar et al., 2015; Scorza et al., 2009b), reduce seizure frequency (Ciarlone et al., 2016; 
Yuen et al., 2005) and improve other health aspects of epileptic patients, others have failed to 
confirm similar findings (Matthews et al., 2012; Sarmento Vasconcelos et al., 2016; Yuen et 
al., 2012).  
 
In veterinary medicine, there remains a lack of data regarding dietary intervention for epilepsy 
management. In comparison to human medicine, few studies exist on the use of nutritional 
management in dogs with IE (Matthews et al., 2012; Scorza et al., 2013; Scorza et al., 2009b). 
In 2004, a trial of eight dogs with drug-resistant epilepsy and signs of gastrointestinal 
hypersensitivity treated with an exclusion diet was reported (Lujan A, 2004). In this 
preliminary study, seven out of eight dogs had a reduction in seizure frequency. In a 
randomised, double-blinded, placebo-controlled study, dogs with IE fed with a medium-chain-
triglyceride (MCT) enriched diet over three months showed significantly lower seizure 
frequency in comparison to placebo diet (Law et al., 2015). Improvements in seizure outcome 
was accompanied by positive modification in attention-deficit/hyperactivity disorder (ADHD) 
related behaviours and potential anxiolytic effects (Packer et al., 2016). The effects of other 
DS in canine epilepsy have been mixed. A positive impact of omega-3 fatty acids (Ω-3 FAs) 
supplementation was reported in one dog with drug-resistant epilepsy (Scorza et al., 2013; 
5 
 
Scorza et al., 2009b). In contrast, Matthews et al. (Matthews et al., 2012) reported no reduction 
in seizure frequency and severity in fifteen dogs with IE when supplemented with and oil 
containing long essential fatty acids (eicosapentaenoic acid, docosahexaenoic acid, Vitamin E) 
for 12 weeks.  
 
Many online epilepsy support groups recommend dietary interventions in epilepsy 
management, often based on anecdotal evidence. Currently, the type of DS recommended from 
owner to owner, the source of their recommendations and exactly which DS owners use for 
their dogs with epilepsy is unknown. As with any ‘therapeutic’ intervention, there is the 
potential that certain dietary interventions could benefit or have no effect, but also potentially 
harm the patient either directly or through diet-drug interactions.  
 
This study aims to increase our understanding on the current use of diets and DS in canine 
epilepsy management. The objectives of this study are: 
(i) To describe owner use of DS and nutritional management in canine IE 
(ii) To describe reasons for and against DS use by owners of dogs with IE 
(iii) To identify information sources utilised by owners to choose DS 
(iv) To describe owner-perceived side effects of DS use 
As DS are becoming increasingly available to owners, this study will equip veterinary surgeons 
with important insights to be considered when managing a patient with IE.  
 
Materials and Methods 
 
From April to June 2017, an online questionnaire study was hosted on SurveyMonkey™ 
(SurveyMonkey Europe, Shelbourne Road, Dublin, Ireland). Owners of dogs with IE were 
recruited via social media. Consent was gained via a statement at the start of the questionnaire, 
and the study was approved by the Royal Veterinary College’s Ethics and Welfare Committee 
(approval number URN 2016 1558).   
 
Epilepsy data 
 
To be included in the analysis, the dog must have met the International Veterinary Epilepsy 
Task Force (IVETF) tier I confidence level for the diagnosis of idiopathic epilepsy (De Risio 
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et al., 2015). Dogs with a history of seizures that did not meet these criteria (e.g. those with 
epilepsy with an identifiable cause, insufficient diagnostic testing, where seizure onset was <6 
months old or >6 years old with no MRI to rule out structural causes) were excluded from the 
study. Only completed questionnaires were considered in the analysis. Based on 
supplementation habits, owners were allocated to one of three groups: (1) owner recently used, 
(2) previously used or (3) never used dietary interventions for epilepsy management. Details 
on their dog’s signalment, seizure phenotype (total number of seizures, number of seizures over 
the last three months, history of cluster seizures and/or status epilepticus), AED medication, 
diet (type, frequency, routine, purchase, and treats) and owner demographics were gathered.  
 
Dietary supplement data 
 
According to the United States Food and Drug Administration (FDA) under the US Dietary 
Supplement Health and Education Act of 1994 ((FDA), 1994) and the European Union's (EU) 
Food Supplements Directive of 2002 (R 2002/46/EG) (UNION, 2002), the term DS is defined 
as a product taken by mouth that contains a dietary ingredient intended to supplement the diet. 
The FDA and EU regulations require supplements to be demonstrated as safe, both in dosages 
and purity. However, these definitions apply to human consumers and not companion animals 
(Vandeweerd et al., 2013). Because the term DS has no overall regulatory or legal definition 
in veterinary medicine, for the purposes of this study, a DS was defined as “an edible product 
added to a dog’s main diet on a regular or irregular basis which is intended to provide 
additional support to health”.  
 
Owners were asked to report details of the DS they currently or previously used in their dogs 
epilepsy management, including what types of DS (> 40 options, others, free input) they 
administered to their dog (if any) and reasons to start or to stop supplementation. In addition, 
owners reported their personal experience of DS use (self-supplementation), way of choosing 
DS for their dog, the way they decided upon their DS-administration regime and their 
individual perception of possible DS effects.  Details of all questions are available in the full 
survey (Supplementary file 1). 
 
Statistical analysis 
 
Data were handled using IBM SPSS (v23.0), Microsoft Excel (v2017) and GraphPad Prism 7. 
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Chi-squared tests were used to investigate the association between owner self-supplementation 
and use of DS in their dog. Data were tested for normality of distribution using the 
Kolmogorov-Smirnov test; variables that were normally distributed are stated as mean ± SD, 
and non-normally distributed stated as median (m, min-max). The continuous data were not 
normally distributed, therefore non-parametric statistic tests were used (Mann-Whitney-U-
Test). All tests were two-sided and p<0.05 was considered to be significant.  
 
Results 
 
Overall, 547 responses were collected, of which 297 were complete and met the inclusion 
criteria. The majority of respondents were female (81.5 %) and aged between 46 to 60 years 
(38.4 %), with 20 years’ experience of dog ownership (20.20 ± 13.9 years). The majority of 
respondents were from the UK (37.4 %), followed by USA (36.7%), Canada (10.4%), Germany 
(6.7%) and Australia (2.4%). Nearly every second owner (47.0%, n=140) included DSs for 
general health (33%, n=99) or a specific condition (14.1%, n=42) into their own diet. Owners 
supplementing their own diets with DS were significantly more likely to give their own dog 
DSs as well (X2=38.620, p=0.001).  
 
The study population consisted mainly of male neutered dogs (52.9 %) with a mean age of 66.7 
± 31.5 months and body weight of 25.1 ± 15.3 kg. With 73 different breeds represented, most 
study dogs were pure-breed (82.5 %), with the most common pure-breed being the Border 
Collie (n=40, 13.5 %).  
 
Epilepsy phenotype  
 
Most owners reported that their dog had generalized seizures (71.0%). The majority of dogs 
currently received AEDs (87.8%, n=261) with the most frequently reported drug being 
phenobarbital (79.3%, n=207), as a monotherapy (23.4%, n=61) or in combination with other 
AEDs (55.1%, n=146). Comparing the daily number of AEDs administered in association to 
the use of DS, dogs who currently or who used to get DS (2, 0-6) were on significantly more 
AEDs per day than dogs not receiving  DS (1, 0-6; p=0.012). 
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Dogs were reported to have had a mean of 6.18 ± 9.7 seizures within the last three months, and 
a mean of 27.22 ± 22.57 during their life to date. Dogs that currently receive DS or used to 
receive DS (25.5, 3-10 seizures) had not suffered from significantly more seizures in their life 
than the dogs not receiving DS (20, 9-30 seizures, p=0.064).   
 
Cluster seizures were reported in more than three-quarters of all dogs (78.1%, N=232), and 
almost a quarter (24.6 %, N=73) were reported to have experienced a seizure that lasted longer 
than 5 minutes without regaining consciousness (status epilepticus). Whilst the occurrence of 
CS was not significantly associated (X²= 2.119, p=0.714) with the administration of DS, dogs 
that experienced SE in past were more likely to receive DS (28%, X²=15.209, p=0.004). 
 
Main dietary regime 
 
In total, two thirds of owners (67.7%) reported to have changed their dog’s diet since diagnosis 
with IE (Fig. 1). The majority of dogs (60.6%) were fed dry food as a complete diet or dry food 
in combination with wet food (25.6%), followed by home-cooked (17.8%) or raw food (21.9 
%) diets. The majority of dogs were fed twice daily (68.0%). Pet shops (39.1 %) or online 
stores (37.4 %) were the most common places of purchase for diet and DS. Less than one-third 
of owners based their dog’s main dietary regimen on the advice of a veterinary surgeon (27.6 
%), with 13.8% basing their feeding regime on information published online, and 37.5% citing 
‘other’ as a source of information.   
 
Dietary supplementation 
 
In the study cohort nearly half of the owners (45.8 %) reported that they currently gave their 
dog DS to manage their dog’s epilepsy. As shown in Figure 2, the most common DS type 
belonged to fatty acid group (94 %). Micro- and macronutrients containing DS were routinely 
given by 66.0% of owners. Over half of dogs received additional vitamins (57.0%) or amino 
acid products (44.0%) alongside their normal food. In most cases, DS were given on a daily 
basis (51.2%, n=80). 
 
The top three most commonly used DS were coconut or coconut-derived oils (N = 112, 77.3%), 
fish or fish-derived oils (N = 105, 66.9%) and milk thistle (N = 67, 42.7%). Other frequently 
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used DS were cannabis oil (N = 66, 42%), Vitamin B12 products (N=39, 24.8%), homeopathic 
remedies (20.4 %), glucosamine and/ or chondroitin (19.1%), taurine (17.2%) and dried herbs 
(15.9%) (Figure 2).  
 
While less than one fifth of owners consulted their vet on the use of DS (17.5%), the most 
common source of advice for DS use was online owner support groups (38.2%) or online 
information (20.6 %). The main reasons given by owners to use DS for their epileptic dog were; 
(i) Reduction of seizure frequency (88.2%), (ii) Protection of the dog’s body from potential 
side effects of AED medication (62.5%) and (iii) Reduction of seizure severity (61.8 %) (Fig. 
3). Other objectives for the use of a DS were to improve the postictal recovery phase (42.6%), 
for the reduction of AED side-effects (41.2%) or epilepsy co-morbidities, such as cognition or 
behavioral issues (30.1%). One third of all owners (34%, n=101) would recommend using DS 
as management for their dog’s epilepsy to other owners.  
 
Cessation of dietary supplementation 
 
A minority of owners in the study population (N = 21) had stopped giving their dog DS, as 
they did not believe it had any recognisable, beneficial effect (33.3%) or were afraid of 
potential damaging side effects (9.5%). In 9.5% of owners, chronic administration of DS was 
stopped because the dog refused to take it. 
 
Non-use of dietary supplementation 
 
Half of study respondents (47.1%, n=140) did not currently, and had not previously given their 
dogs DS. More than half of this group were not aware of DS (57.8%). Other reasons for not 
using DS in epilepsy management included feeling uncomfortable giving DS without 
veterinary supervision (32.1%), needing scientific evidence on beneficial effects in epilepsy 
management for them to be used (11.4%) or were afraid of potentials harms associated with 
DS (11.4%). However, 92.5 % of owners (N = 149) who stopped or had never previously used 
DS would reconsider DS administration when more scientific evidence would support such 
products.  
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Common side-effects of used DS 
 
Overall, side effects associated to DS administration were not frequently reported by owners 
(N=157, of those who currently or previously used DS). However, the most common adverse 
events seen with DS consumption in dogs were sedation (18.5%, N =29), followed by more 
frequent water intake (14.6%, N = 24) and weight gain (14.6%, N=22). 
 
Discussion 
 
Dietary modification and supplementation is common in dogs with epilepsy; two thirds of 
owners adjusted their dog’s diet after diagnosis of IE and nearly half gave DS as additional 
management. As pharmacokinetic properties of AEDs are known to be influenced by other 
medications (Munana et al., 2015) or diets (Gindiciosi et al., 2014; Munana et al., 2015; 
Patsalos, 2000; Rundfeldt et al., 2014; Shaw et al., 1996; Thurman et al., 1990), different DS 
may also affect their efficacy, absorption and excretion (Kverneland et al., 2015; Larsen et al., 
2014). As such, awareness of safe DS-AED combinations and feeding practices is of 
importance to owners and veterinary surgeons alike. For example, high dietary chloride content 
is associated with a decrease in therapeutic serum bromide concentrations and increased seizure 
frequency in epileptic dogs (Shaw et al., 1996). Likewise, a pharmacokinetic study showed that 
dietary protein or fat restriction significantly increased the clearance and elimination rate of 
phenobarbital (Maguire et al., 2000). As such, dogs on chronic AEDs should be kept on a 
relatively constant diet regime. 
 
Although data on the efficacy, safety, or beneficial effects of different DSs on canine epilepsy 
are lacking (Bontempo, 2005; Law et al., 2015; Manteca, 2011; Matthews et al., 2012; Pan et 
al., 2010; Scorza et al., 2009a), and where evidence is available, it is mostly reported in humans 
(Gaby, 2007; Gilby et al., 2009; Grey and Bolland, 2014; Pearl et al., 2011; Widenhorn-Muller 
et al., 2014; Yuen et al., 2012; Yuen and Sander, 2012; Yuen et al., 2005), DS are commonly 
used by owners to manage their dogs epilepsy. The current study showed that various oils are 
often used as DS for dogs with IE. In one third of epileptic dogs treated with potassium bromide 
or phenobarbital long-term, there may be an increased risk of pancreatitis due to induced 
hypertriglyceridemia (Bossens et al., 2016; Kluger et al., 2008; Thomas, 2010). Accordingly, 
for dogs receiving additional oil DS on a daily basis (James et al., 2009), it may be 
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recommendable to monitor serum triglyceride concentration and canine pancreas-specific 
lipase (Albarracin et al., 2015) more periodically than usual to avoid complications. The 
influence of dietary long-chain fatty acids on the absorption and excretion of commonly used 
AEDs should also be considered; a previous clinical trial of dietary effects on the 
pharmacokinetics of phenobarbital found that fat may be able to increase absorption rate and 
decrease drug clearance (Maguire et al., 2000).  
 
The most common DS in this study, consumed by more than 75% of epileptic dogs, was 
coconut oil or the derived MCT oil.  MCT oils typically contain large amounts of MCTs and 
glyceroesters with saturated 8- to 12-carbon fatty acids, with an absence of long-chain 
triglycerides (LCTs) (St-Onge and Jones, 2002). The main constituents, octanoic (C8; caprylic) 
and decanoic (C10; capric) triglycerides (TAGs), along with their downstream metabolites, are 
thought to have antiepileptic effects (Chang et al., 2013). A recent study revealed that decanoic 
acid acting as a non-competitive AMPA receptor antagonist results in direct inhibition of 
excitatory neurotransmission, and thus exerts an anticonvulsant effect (Chang et al., 2015). 
Beta-hydroxybutyrate (BHB) has been shown to reduce seizure-like neuronal activity and is 
thought to assert its effectiveness via KATP channel activity and inhibition of GABAB signalling 
in a Drosophila in vitro model (Li et al., 2017). Furthermore, oral MCT supplementation leads 
to significant elevation in ketone BHB concentrations and improved seizure control in dogs 
(Law et al., 2016). .Whether ketogenic MCTs as purified oil or within coconut oil can be both 
an effective anticonvulsant in dogs with IE requires further investigation.  
 
The second most mentioned DS, fish oils, commonly contains higher amounts of Ω-3 FAs 
(Bauer, 2011, 2016) contributing to CNS development and reducing risk of neurological 
disorders such as epilepsy (Bourre, 2004). These fatty acids can modulate ion channels, and 
have been described to induce mechanisms of action in reducing excitability within the CNS 
(DeGiorgio and Taha, 2016). While in humans, Ω-3 FAs have been shown to reduce seizure 
frequency in chronic epilepsy (Yuen et al., 2005), there little evidence in dogs with IE. In a 
single case report, addition of Ω-3 FAs had a positive impact on seizure occurrence and 
subjective QoL in a dog with drug-resistant IE (Scorza et al., 2009b). This efficacy was, 
however, not confirmed in a placebo controlled twelve-week long study using a Ω-3 FAs DS 
for dogs with IE (Matthews et al., 2012). Further evidence is needed to explore the potential of 
Ω-3 FAs in the management of IE in dogs.  
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Dried herbs, including milk thistle, valerian, skullcap or Chinese herb mixtures, were reported 
to be given by dog owners for epilepsy management. In particular, milk thistle products are 
frequently used in epileptic dogs to try to prevent AED hepatotoxicity. All aforementioned 
supplements have been recommended for use in epilepsy in humans, or the rationale for their 
antiepileptic action are critically discussed in a study of US adults (Wells et al., 2010). 
Paradoxically, some dried herbs are reported to have more inadvertent seizure provoking than 
anticonvulsant effects (Pearl et al., 2011).  Milk thistle (Silybum marianum) is a commercially 
available hepatoprotective product available in diverse forms (dried herbs, extracts, oil, tablets) 
(Pradhan and Girish, 2006). Antioxidant (Pradhan and Girish, 2006), cytoprotective and anti-
inflammatory properties mean that milk thistle in used in the treatment of liver diseases in 
humans (Trappoliere et al., 2009) and in dogs (Vandeweerd et al., 2013; Webster and Cooper, 
2009). Substantial in vitro and in vivo evidence suggest that silymarin can protect the liver 
from toxin, drug and ischemic-induced injuries (Marjani et al., 2016; Muriel and Mourelle, 
1990; Pradhan and Girish, 2006; Vogel et al., 1984). Most findings were made in humans with 
a variety of liver conditions, and these beneficial properties must be reassessed in dogs. Most 
recently, based on in-vitro experiments, flavonoid compounds were proposed as reversing 
agents for multidrug resistance against several AEDs, and in humans have been demonstrated 
to being able to increase intracellular concentrations (Ferreira et al., 2018). Therefore, chronic 
oral supplementation of milk thistle might protect the liver from damage, but paradoxically 
may increase the plasma concentration of certain AEDs and therefore potentially aggravate the 
hepatotoxic effect of some of the AEDs.  
 
Other herbal products, aqueous extracts of Valerian or Baldrian showed anticonvulsant effects 
in animal models, likely to be mediated through activation of the adenosine system (Giraldo et 
al., 2010; Rezvani et al., 2010; Torres-Hernandez et al., 2015; Verma and Thuluvath, 2007). 
To date, there is insufficient data on the safe and efficacious application of these herbs for 
canine epilepsy management.  
 
Recently, the medicinal use of cannabidiol (CBD) in people has become widespread especially 
for neurological disorders (Solimini et al., 2017). Although at present there is limited scientific 
evidence on its efficacy and safety (Iffland and Grotenhermen, 2017), independent use has 
become popular in people (Fairman, 2016; Whiting et al., 2015). CBD oil was reported to 
effectively reduce seizure frequency and duration in humans and some animal models 
(Devinsky et al., 2016; Kaplan et al., 2017); however, information on toxicological parameters 
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from long-term administration are lacking (Iffland and Grotenhermen, 2017). The underlying 
physiological and molecular mechanisms mediating beneficial therapeutic effects have not yet 
been explored. In human medicine, CBD oil was recently shown to increase the serum level of 
commonly used AEDs with increasing CBD dose (Gaston et al., 2017). Cannabis, however can 
be toxic for dogs (Meola et al., 2012).  There are now ongoing studies on the effects of CBD 
in dogs with epilepsy that will shed light in this area on efficacy and safety (Colorado State 
University).  
 
Vitamin B was part of their daily regime of 25% of dogs receiving DS. Vitamin B1 or thiamine 
is known to be an essential factor in a number of different biochemical pathways in the brain. 
A deficiency can result in progressive encephalopathy, neuropathies and seizure occurrence 
(Garosi et al., 2003; Markovich et al., 2013; Zera and Zastre, 2017). A link between 
neurotransmitter production and thiamine availability has been discussed (Cheney et al., 1969); 
however, in comparison to cats, dogs are less susceptible to thiamine deficiency. Dietary 
restriction (Baird and Ravindranath, 2015) or some diet components might be capable of 
decreasing adequate thiamine absorption (Singh et al., 2005). Excessive prolonged epileptic 
episodes are linked to oxidative brain damage often related to mitochondrial dysfunction 
through an increase of free oxygen radicals in neuronal cells (Cardenas-Rodriguez et al., 2013; 
Loscher, 2002; Markowitz et al., 2010). Therefore, molecules such as thiamine that have been 
shown to have positive and preventive effects on drug induced oxidative stress (Turan et al., 
2014a) are of great interest in epilepsy treatment.. There is no reliable evidence to support the  
routine use of any other vitamins in human patients with epilepsy to date (Ranganathan and 
Ramaratnam, 2005). Further long-term studies are required to elucidate the potential benefits 
of vitamin supplementation, and whether they may prevent or reverse the effects of deficiencies 
that result from epileptic seizures or the use of AEDs (Gaby, 2007).  
 
In one third of owners, management of cognitive and behavioural co-morbidities of epilepsy 
was a reason for DS use. Although we are just beginning to understand the behavioural and 
cognitive comorbidities of epilepsy in the dog, many of the neurobehavioral comorbidities 
observed in human epilepsy patients are being discovered in dogs with epilepsy, including 
anxiety (Shihab et al., 2011), ADHD-like behaviour (Jokinen et al., 2015; Packer et al., 2016) 
and cognitive impairments (Packer et al., 2016; Packer et al., 2018a; Packer et al., 2018b; 
Winter et al., 2018). An increasing number of studies report significant impacts of diets on 
canine behaviour (Munana, 2013; Orlando, 2018; Shihab et al., 2011). As dietary ingredients 
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are precursors of many neurotransmitters involved in regulation of behaviour and can alter 
cerebrospinal fluid composition (Delion et al., 1994; DeNapoli et al., 2000; Galan et al., 2014), 
changes in the diet composition could conceivably influence behaviour (Bosch et al., 2007). 
The growing interest on risk factors for prevention and attenuation of cognitive decline in older 
dogs has led to an unprecedented interest in the relationship between diet and cognitive 
function (Di Cerbo et al., 2017b; Overall, 2011; Snigdha et al., 2016). Nutritional interventions 
to delay cognitive ageing are becoming increasingly important. A recent study reported that 6 
months of supplementation with a nutrient blend consisting of antioxidants, B vitamins, fish 
oil and l-arginine, can have cognition-improving effects on aged dogs between 9 and 11.5 years 
old (Pan et al., 2018). In addition, studies have found that brain function of aged dogs was 
significantly improved by a specific diet formula with 5.5% MCT content. Therefrom, it was 
hypothesized that this occurs from MCT consumption providing the brain with an alternative 
energy source through an increasing ketone body level (Pan et al., 2010).  
 
This study has a number of limitations; primarily that owners in this population may not be 
representative of all epileptic dog owners: owners of dogs with more severe epilepsy 
phenotypes may be more likely to use online support groups due to higher levels of 
psychological stress and need for peer-peer support (D'Aniello et al., 2017; Packer et al., 2017; 
Wessmann et al., 2014), and the study population was heavily biased towards female owners.  
As reported here, vets were rarely the source of information owners used to discuss diet or the 
use of DS as management tools for their dog’s epilepsy. These data on the relatively high 
prevalence of DS use in canine epilepsy aim to inform and empower vets to engage with clients 
on this topic, and encourage active discussion on their clients’ epilepsy management beyond 
traditional drug treatment. Potential interactions of DS with AEDs are yet to be explored, and 
thus we must consider that DS may pose dangers to epileptic patients. With a paucity of data 
on the short- and long-term effects of DS on dogs with epilepsy, caution should be exercised 
when discussing or recommending such products. A greater understanding of the owners of 
chronically ill patients, including the role of parenting styles in the owner-dog relationship 
(Herwijnen et al., 2018), peer-peer support and the internet as information sources (Belshaw et 
al., 2016) should be explored further to better understand owner decision-making in their dog’s 
treatment. Interestingly, owners who supplemented their own diet had a higher tendency to 
give DS to their dogs. This emphasizes a link between an owner’s perception of their own 
nutrition and their pet’s diet. 
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Conclusions  
 
There remains limited knowledge about the benefits of DS in canine epilepsy management; 
however, an increasing number of studies are being published in this area and many owners of 
dogs with IE already use DS to help manage canine epilepsy without evidence to support their 
use. As such, and veterinary surgeons should be aware of this activity and actively engage with 
their clients to discuss the management of these patients beyond the drugs they prescribe. Diet 
composition, content and some of the DS mentioned could influence pharmacokinetic 
properties of AEDs and potentially modulate their efficacy and safety profile (Berendt et al., 
2015; Floerchinger et al., 2015; Scorza et al., 2009b). Canine nutrition needs to be considered 
when taking a clinical history for clinical trials (Di Cerbo et al., 2017a) and we recommend 
that all vets collect information on diet and DS use as part of a dietary history in epilepsy cases.  
The general use of DS should be considered and monitored by veterinary surgeons in long-
term epilepsy management and the chronic intake of different DS types should be re-evaluated 
and adjusted in the process of therapeutic intervention for better seizure control. Future 
experimental, epidemiological and clinical studies are needed to evaluate the potential benefits 
and harms of the various DS reported here in epilepsy management. Understanding the 
complex interplay between medication and diet will improve future management of epileptic 
patients in veterinary medicine. 
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Table 1: The most common DS side effects reported by owners 
Side-effect 
 
Not 
present 
Present 
Very 
mild 
Mild Moderate Severe 
Very 
Severe 
Sleeping more than before 81.5% 18.5% 9.6% 4.5% 3.2% 0 1.3% 
Drinking more 84.7% 15.3% 6.4% 6.4% 1.9% 0.6% 0 
Gaining weight 85.4% 14.6% 5.7% 3.8% 3.8% 1.3% 0 
Urinating more 87.9% 12.1% 3.8% 4.5% 3.2% 0.6% 0 
Wobbly/ not coordinated 
when walking 93.6% 6.4% 3.2% 1.9% 0 0.6% 0.6% 
Restlessness/ Pacing 93.6% 6.4% 4.5% 0.6% 0.6% 0 0.6% 
Itchiness or skin rash 91.7% 8.3% 3.2% 1.3% 3.8% 0 0 
Diarrhea 91.7% 8.3% 5.1% 2.5% 0 0 0.6% 
Coughing 86% 14.0% 2.5% 5.7% 4.5% 0.6% 0.6% 
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Figure captures 
 
 
Figure 1: Alteration of Diet and Use of Dietary Supplement for Epilepsy Management – 
The bar charts illustrate the number of owners in percent (%) altered their dogs diet or 
administer DS with the aim of achieving better epilepsy management. Over two-third of owners 
have altered their dogs diet, while every second started to supplement. Over 60% of owners 
giving their dog DS currently use DS in their own dietary plan.  
Figure 2: Types of DS in use for Epilepsy Management – Almost every second owner give 
DS to manage their dog`s epilepsy from the nutritive side. The distribution scaled in percent of 
owners (%) about used DS types highlight the main use of oil DS. Every two out of three 
epileptic dogs under dietary supplementation receives coconut, fish or from these derived oils 
as add-on. Beside oils, micro- and macronutrient or vitamin containing DS appeared to be the 
second often administered products. 
Figure 3: Owner`s reasons to use or not to use DS as additional support for their dog`s 
epilepsy management – Reasons to give or not to give DS can come from different source. 
The bar charts show up in per cent of all owners (%) why decided to put their dog on DS or 
withheld nutritive add-ons from their dog’s food.  
Figure 4: Owner`s reasons to stop using DS as additional management for their dog`s 
epilepsy – A small portion of the study population stopped to administer DS in the past.  The 
reasons why they quitted nutritive supplementation are summarized as bar chart in percent of 
owners.  
 
 
Supplementary Files 
 
Supplementary Files 1: Owner questionnaire to investigate the use of dietary supplements in 
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side. The distribution scaled in percent of owners (%) about used DS types highlight the main use of oil DS. Every two out of three epileptic dogs 
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Figure 3: Owner`s reasons to use or not to use DS as additional support for their dog`s epilepsy management – Reasons to give or not to 
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Figure 4: Owner`s reasons to stop using DS as additional management for their dog`s epilepsy – A small portion of the study population 
stopped to administer DS in the past.  The reasons why they quitted nutritive supplementation are summarized as bar chart in percent of owners.  
 
 
